Evidence map›Paper›PMID 37878345›Full record

ArticleMolecular cancer research : MCR2024

Spatial Transcriptomics Suggests That Alterations Occur in the Preneoplastic Breast Microenvironment of BRCA1/2 Mutation Carriers.

Anthony Caputo, Kavya Vipparthi, Peter Bazeley, Erinn Downs-Kelly, Patrick McIntire, Lauren A Duckworth, Ying Ni, Bo Hu, Ruth A Keri, Mihriban Karaayvaz

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Anthony CaputoGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.ORCID 0009-0006-8649-2588
Kavya VipparthiGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0002-5656-3166
Peter BazeleyDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0002-6272-5686
Erinn Downs-KellyDepartment of Pathology, Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio.ORCID 0009-0003-7043-949X
Patrick McIntireDepartment of Pathology, Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0002-5972-4586
Lauren A DuckworthDepartment of Pathology, Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0002-6866-6760
Ying NiCenter for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0002-0338-5239
Bo HuDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0003-0606-7639
Ruth A KeriDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0002-1640-3088
Mihriban KaraayvazGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0002-6264-2477
Cleveland Clinic Lerner College of Medicine · USCleveland Clinic · US

Funding

Supplement - Discovering the role of YES1 in triple negative breast cancerR01CA257502 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI KERI, RUTH A. · 2021 to 2025
$2.8M
Elucidating and Leveraging the mTOR Negative Feedback Pathway in Breast CancerR01CA213843 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI KERI, RUTH A. · 2017 to 2021
$2.0M
NCI NIH HHS R01 CA213843NCI NIH HHS R01 CA257502
6 · The paper itself

Abstract

Breast cancer is the most common cancer in females, affecting one in every eight women and accounting for the majority of cancer-related deaths in women worldwide. Germline mutations in the BRCA1 and BRCA2 genes are significant risk factors for specific subtypes of breast cancer. BRCA1 mutations are associated with basal-like breast cancers, whereas BRCA2 mutations are associated with luminal-like disease. Defects in mammary epithelial cell differentiation have been previously recognized in germline BRCA1/2 mutation carriers even before cancer incidence. However, the underlying mechanism is largely unknown. Here, we employ spatial transcriptomics to investigate defects in mammary epithelial cell differentiation accompanied by distinct microenvironmental alterations in preneoplastic breast tissues from BRCA1/2 mutation carriers and normal breast tissues from noncarrier controls. We uncovered spatially defined receptor-ligand interactions in these tissues for the investigation of autocrine and paracrine signaling. We discovered that β1-integrin-mediated autocrine signaling in BRCA2-deficient mammary epithelial cells may differ from BRCA1-deficient mammary epithelial cells. In addition, we found that the epithelial-to-stromal paracrine signaling in the breast tissues of BRCA1/2 mutation carriers is greater than in control tissues. More integrin-ligand pairs were differentially correlated in BRCA1/2-mutant breast tissues than noncarrier breast tissues with more integrin receptor-expressing stromal cells. IMPLICATIONS: These results suggest alterations in the communication between mammary epithelial cells and the microenvironment in BRCA1 and BRCA2 mutation carriers, laying the foundation for designing innovative breast cancer chemo-prevention strategies for high-risk patients.

Indexed as

BRCA1 ProteinBreast NeoplasmsBRCA2 ProteinFemaleGene Expression ProfilingGenes, BRCA1Genetic Predisposition to DiseaseGerm-Line MutationHumansIntegrinsLigandsMutationTumor MicroenvironmentBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanIntegrinsLigands

Identifiers

PMID37878345
PMCPMC10872731
OpenAlexW4387931519

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.